US 11,701,415 B2
Oil-based adjuvants
Paul Joseph Dominowski, Kalamazoo, MI (US); Dennis L. Foss, Mattawan, MI (US); Guillermo Gallo, Kalamazoo, MI (US); John Morgan Hardham, Kalamazoo, MI (US); Richard Lee Krebs, Ashland, NE (US); Sandra Ann Marie Lightle, Kalamazoo, MI (US); Suman Mahan, Kalamazoo, MI (US); Sangita Mediratta, Kalamazoo, MI (US); Kaori Mohr, Kalamazoo, MI (US); Duncan Mwangi, Portage, MI (US); Sharath K. Rai, Portage, MI (US); Sarah A. Salmon, Kalamazoo, MI (US); Shaunak Vora, Kalamazoo, MI (US); and Lauren Wilmes, Lincoln, NE (US)
Assigned to Zoetis Services LLC, Parsippany, NJ (US)
Filed by Zoetis Services LLC, Parsippany, NJ (US)
Filed on Feb. 16, 2021, as Appl. No. 17/176,749.
Application 17/176,749 is a continuation of application No. 16/166,455, filed on Oct. 22, 2018, granted, now 10,953,080.
Application 16/166,455 is a continuation of application No. 14/491,414, filed on Sep. 19, 2014, granted, now 10,117,921, issued on Nov. 6, 2018.
Claims priority of provisional application 61/879,959, filed on Sep. 19, 2013.
Prior Publication US 2021/0170013 A1, Jun. 10, 2021
Int. Cl. A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61K 9/107 (2006.01); G01N 33/569 (2006.01); C12N 7/00 (2006.01); A61K 39/09 (2006.01); A61K 39/012 (2006.01); A61K 39/108 (2006.01); A61K 39/05 (2006.01); A61K 39/08 (2006.01); A61K 39/118 (2006.01); A61K 39/39 (2006.01); A61K 39/002 (2006.01); A61K 39/085 (2006.01)
CPC A61K 39/092 (2013.01) [A61K 39/0002 (2013.01); A61K 39/002 (2013.01); A61K 39/0003 (2013.01); A61K 39/0005 (2013.01); A61K 39/012 (2013.01); A61K 39/0258 (2013.01); A61K 39/05 (2013.01); A61K 39/08 (2013.01); A61K 39/085 (2013.01); A61K 39/118 (2013.01); A61K 39/12 (2013.01); A61K 39/39 (2013.01); G01N 33/56944 (2013.01); A61K 2039/552 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/55566 (2013.01); A61K 2039/55572 (2013.01); A61K 2039/55577 (2013.01); A61K 2039/55583 (2013.01); G01N 2333/315 (2013.01); G01N 2469/10 (2013.01); Y02A 50/30 (2018.01)] 7 Claims
 
1. A vaccine composition comprising a Rhipicephalus microplus antigen and an adjuvant, said adjuvant being selected from the group consisting of:
a) an aqueous adjuvant comprising an immunostimulatory oligonucleotide, a saponin, a sterol, a quaternary amine, a polyacrylic polymer, and a glycolipid; and
b) an oil-based adjuvant, comprising an oily phase present in the amount of at least 45% v/v of the vaccine composition and comprising an immunostimulatory oligonucleotide and a polycationic carrier, wherein said vaccine composition is a water-in-oil emulsion.